Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors.

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Dual targeting of EGFR and HER2 is a key strategy in cancer therapy.
• Purine-containing hydrazones represent a novel class of potential anticancer agents.
• Understanding kinase inhibition mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

• To design, synthesize, and evaluate novel purine-containing hydrazones (6-24a,b) as anticancer agents.
• To investigate the in silico binding affinity of these compounds to EGFR and HER2 kinase domains.
• To assess the in vitro antiproliferative and kinase inhibitory activities of the synthesized compounds.

Main Methods:

• In silico molecular docking for binding affinity assessment.
• Chemical synthesis of purine-containing hydrazone derivatives.
• In vitro antiproliferative assays (MTT) against A549, SKOV-3, A2780, and SKBR-3 cancer cell lines.
• In vitro kinase inhibition assays for EGFR and HER2.
• Cell cycle analysis and apoptosis detection via flow cytometry.

Main Results:

• Compounds 19a, 16b, and 22b exhibited significant antiproliferative activity.
• Compound 19a showed superior efficacy against A549 and SKBR-3 cells compared to lapatinib.
• Compounds 19a, 16b, and 22b demonstrated potent EGFR inhibition, with 22b showing equipotent HER2 inhibition to lapatinib.
• Cell cycle arrest at G1 phase and apoptosis induction were observed with 19a and 22b treatment.

Conclusions:

• Compounds 19a, 16b, and 22b are promising candidates for developing novel anticancer drugs.
• These compounds effectively target EGFR and HER2 kinases.
• Further investigation into these hydrazone derivatives could lead to new targeted cancer therapies.